Guideline Concordant Therapy Prolongs Survival in HER2-Positive Breast Cancer Patients: Results from a Large Population-Based Cohort of a Cancer Registry

Table 1

Time dependent rates of HER2 analyses.

Year of diagnosis	Number of patients (𝑁)	HER2 status unknown (𝑁, %)	HER2 status analyzed (𝑁, %)	HER2 negative (𝑁, %)	HER2 positive (𝑁, %)
2000	430	360 (83.7%)	70 (16.3%)	49 (70.0%)	21 (30.0%)
2001	456	137 (30.0%)	319 (70.0%)	236 (74.0%)	83 (26.0%)
2002	455	72 (15.8%)	383 (84.2%)	304 (79.4%)	79 (20.6%)
2003	518	68 (13.1%)	450 (86.9%)	351 (78.0%)	99 (22.0%)
2004	568	52 (9.2%)	516 (90.8%)	421 (81.6%)	95 (18.4%)
2005	569	34 (6.0%)	535 (94.0%)	438 (81.9%)	97 (18.1%)
2006	527	8 (1.5%)	519 (98.5%)	409 (78.8%)	110 (21.2%)
2007	570	34 (6.0%)	536 (94.0%)	439 (81.9%)	97 (18.1%)
2008	560	47 (8.4%)	513 (91.6%)	423 (82.5%)	90 (17.5%)
2009	666	5 (0.8%)	661 (99.2%)	544 (82.3%)	117 (17.7%)
2010	589	6 (1.0%)	583 (99.0%)	469 (80.4%)	114 (19.6%)
2011	543	2 (0.4%)	541 (99.6%)	476 (88.0%)	65 (12.0%)
2012	540	2 (0.4%)	538 (99.6%)	471 (87.5%)	67 (12.5%)
Total	6991	827 (11.8%)	6164 (88.2%)	5030 (81.6%)	1134 (18.4%)